| Characterization of drug delivery particles produced by supercritical carbon dioxide technologies O Nuchuchua, MR Nejadnik, SC Goulooze, NJ Lje¹koviæ, HA Every, ... The Journal of supercritical fluids 128, 244-262, 2017 | 44 | 2017 |
| Population pharmacokinetics of vancomycin in obesity: finding the optimal dose for (morbidly) obese individuals C Smit, RE Wasmann, SC Goulooze, MJ Wiezer, EPA van Dongen, ... British journal of clinical pharmacology 86 (2), 303-317, 2020 | 43 | 2020 |
| Lomitapide SC Goulooze, AF Cohen, R Rissmann British journal of clinical pharmacology 80 (2), 179, 2015 | 38 | 2015 |
| Beyond the randomized clinical trial: innovative data science to close the pediatric evidence gap SC Goulooze, LB Zwep, JE Vogt, EHJ Krekels, T Hankemeier, ... Clinical Pharmacology & Therapeutics 107 (4), 786-795, 2020 | 30 | 2020 |
| Model‐based exposure‐response analysis to quantify age related differences in the response to scopolamine in healthy subjects R Alvarez‐Jimenez, GJ Groeneveld, JMA van Gerven, SC Goulooze, ... British journal of clinical pharmacology 82 (4), 1011-1021, 2016 | 25 | 2016 |
| Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours SC Goulooze, P Galettis, AV Boddy, JH Martin Cancer chemotherapy and pharmacology 78, 209-216, 2016 | 25 | 2016 |
| Towards personalized treatment of pain using a quantitative systems pharmacology approach SC Goulooze, EHJ Krekels, M Van Dijk, D Tibboel, PH van der Graaf, ... European Journal of Pharmaceutical Sciences 109, S32-S38, 2017 | 24 | 2017 |
| An anti‐nicotinic cognitive challenge model using mecamylamine in comparison with the anti‐muscarinic cognitive challenge using scopolamine AC Baakman, R Alvarez‐Jimenez, R Rissmann, ES Klaassen, J Stevens, ... British journal of clinical pharmacology 83 (8), 1676-1687, 2017 | 21 | 2017 |
| Renal effects of antisense-mediated inhibition of SGLT2 L van Meer, M Moerland, M van Dongen, B Goulouze, M de Kam, ... Journal of Pharmacology and Experimental Therapeutics 359 (2), 280-289, 2016 | 21 | 2016 |
| Finerenone dose–exposure–serum potassium response analysis of FIDELIO-DKD phase III: the role of dosing, titration, and inclusion criteria SC Goulooze, N Snelder, A Seelmann, A Horvat-Broecker, M Brinker, ... Clinical Pharmacokinetics, 1-12, 2022 | 18 | 2022 |
| Olaparib SC Goulooze, AF Cohen, R Rissmann British Journal of Clinical Pharmacology 81 (1), 171-173, 2016 | 18 | 2016 |
| Bedaquiline SC Goulooze, AF Cohen, R Rissmann British journal of clinical pharmacology 80 (2), 182, 2015 | 17 | 2015 |
| A prospective clinical study characterizing the influence of morbid obesity on the pharmacokinetics of gentamicin: towards individualized dosing in obese patients C Smit, RE Wasmann, SC Goulooze, EJ Hazebroek, EPA Van Dongen, ... Clinical Pharmacokinetics 58, 1333-1343, 2019 | 15 | 2019 |
| Dosing recommendations for vancomycin in children and adolescents with varying levels of obesity and renal dysfunction: a population pharmacokinetic study in 1892 children aged … C Smit, SC Goulooze, RJM Brüggemann, CM Sherwin, CAJ Knibbe The AAPS Journal 23 (3), 53, 2021 | 14 | 2021 |
| Kernel-based visual hazard comparison (kbVHC): a simulation-free diagnostic for parametric repeated time-to-event models SC Goulooze, PAJ Välitalo, CAJ Knibbe, EHJ Krekels The AAPS journal 20, 1-11, 2018 | 13 | 2018 |
| The influence of normalization weight in population pharmacokinetic covariate models SC Goulooze, S Völler, PAJ Välitalo, EAM Calvier, L Aarons, EHJ Krekels, ... Clinical pharmacokinetics 58, 131-138, 2019 | 12 | 2019 |
| Dose–exposure–response analysis of the nonsteroidal mineralocorticoid receptor antagonist finerenone on UACR and eGFR: an analysis from FIDELIO-DKD SC Goulooze, HJL Heerspink, M van Noort, N Snelder, M Brinker, ... Clinical Pharmacokinetics 61 (7), 1013-1025, 2022 | 11 | 2022 |
| The effect of ibuprofen exposure and patient characteristics on the closure of the patent ductus arteriosus in preterm infants AGJ Engbers, S Völler, RB Flint, SC Goulooze, J de Klerk, EHJ Krekels, ... Clinical Pharmacology & Therapeutics 112 (2), 307-315, 2022 | 9 | 2022 |
| Pharmacokinetics and pharmacodynamics of oral mecamylamine–development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation R Alvarez-Jimenez, AC Baakman, J Stevens, SC Goulooze, EP Hart, ... Journal of Psychopharmacology 31 (2), 192-203, 2017 | 7 | 2017 |
| Mirabegron SC Goulooze, AF Cohen, R Rissmann British Journal of Clinical Pharmacology 80 (4), 762-764, 2015 | 7 | 2015 |
